As the med tech industry casts its eye toward neurological implants that improve patient outcomes, researchers are developing a non-invasive technology that could protect against fatal complications by measuring blood flow in the brain.
Takeda Pharmaceutical has stepped up with a $25 million investment in Cleveland's BioMotiv, buying into the accelerator's promise to transform academic discoveries into market-bound therapeutics.
Novo Nordisk has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire up some investigators as it expands its research palate.
We've seen what happens when a big drug goes generic. Plants close, sales reps lose their jobs. As the impending shutdown of a Teva Pharmaceutical Industries unit shows, the same is true for an on-patent drug flop.
LabCorp said it will pay more than $85 million in cash for LipoScience in a bid to grow its own roster of personalized diagnostic tests. The deal, which breaks down to $5.25 per share, is yet another sign that personalized medicine is becoming more ubiquitous in the marketplace.
Regado had all of its eggs in one basket when it took its lead therapy into a Phase III trial on its own. And now that the anticoagulant study has been shelved after signs of a severe allergic reaction were seen among patients, the biotech is cutting more than half of its staffers in an effort to preserve cash and review what kind of moves it can still make.
Back at the beginning of this month, Seattle-based VentiRx spread the news that it had raised a venture round for its newly fast-tracked TLR8 cancer vaccine research, but didn't disclose just how much it had in hand. A new filing at the SEC, though, puts the venture figure at $50.6 million, with another $2.4 million or so left to add in the planned raise.
The U.S. drugmaker will build a new campus in New Jersey for about 2,500 that it promises will pump up "collaboration, creativity and innovation," much as Biogen Idec, Novartis and others have done before it.
Last week the FDA cracked down hard on low-T therapies. Its expert panel voted to advise the agency to restrict the use of such drugs for a specific medical need.
After two false starts in the summer, drug delivery company Microlin Bio is once again withdrawing its planned IPO due to unfavorable market conditions. It had hoped to raise $28 million by offering 5.1 million shares on the Nasdaq priced between $4.50 and $5.50, Renaissance Capital reports.